Press Releases

Feb 28, 2022 8:00 am EST PHASE II CLINICAL STUDY AT WEILL CORNELL MEDICAL CENTER INVESTIGATING PAXALISIB IN COMBINATION WITH METFORMIN AND A KETOGENIC DIET ENROLLS FIRST PATIENT

Feb 7, 2022 8:00 am EST KAZIA THERAPEUTICS TO PRESENT AT BIO CEO CONFERENCE

Jan 25, 2022 8:00 am EST KAZIA THERAPEUTICS TO PARTICIPATE IN EDISON GROUP'S GLOBAL HEALTHCARE 'OPEN HOUSE' VIRTUAL CONFERENCE

Jan 7, 2022 8:00 am EST KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT BIOCONNECT CONFERENCE

Dec 13, 2021 11:00 am EST KAZIA THERAPEUTICS APPOINTS KAREN KRUMEICH AS CHIEF FINANCIAL OFFICER

Dec 4, 2021 8:00 am EST Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma

Nov 29, 2021 8:00 am EST GBM AGILE Opens to Paxalisib in Canada

Nov 15, 2021 11:00 am EST Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer

Nov 11, 2021 8:00 am EST PNOC Study in Childhood Brain Cancer Enrols First Patient

Nov 4, 2021 8:00 am EDT Kazia Enrols First Patient to EVT801 Phase I Clinical Trial